HK Stock Market Move | JIANGXI BIO (06915) once dropped over 14%, with net profit for the first half of the year decreasing by 61% year-on-year and revenue falling by approximately 16.5%.

JIANGXI BIO (06915) once dropped over 14%. Notably, the stock had reached a high of HKD 21.1 the previous day, setting a new high since its listing. As of the time of writing, it was down 8.83%, trading at HKD 18.18, with a transaction volume of HKD 7.2143 million. On the news front, on August 31, JIANGXI BIO announced its interim results for 2026, reporting revenue of HKD 83.3 million, a year-on-year decrease of approximately 16.5%; R&D expenses were HKD 11 million, an increase of 18.6% year-on-year; net profit was HKD 14.366 million, down 61% year-on-year; and the adjusted net profit, excluding one-time items such as listing expenses and tax rate adjustments, was about HKD 38.7 million, a year-on-year decrease of 21.7%. The changes in performance were primarily attributed to increased R&D expenses; adjustments in national tax policies; a decrease in investment income; increased depreciation of fixed assets; and one-time listing expenses. The core product, human TAT, generated sales revenue of approximately HKD 77.5 million during the period, with sales volume of about 9.577 million doses, including approximately 5.911 million doses domestically and about 3.666 million doses overseas. The group continues to promote the dual packaging of ampoules and vials and expand into the end market, actively increasing operational resilience. In terms of the domestic market, it covers 27,100 medical institutions; among them, vial products have completed registration on the pharmaceutical procurement platforms of 32 provinces and cities and achieved inter-provincial alliance procurement in 26 provinces and municipalities.